XML 31 R18.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Restructuring and Other Expense | 12 Months Ended
--- | ---
Dec. 31, 2015
Restructuring Expenses and Other Operating Expenses [Abstract] |
Restructuring and Other Expense | Restructuring and Other Expense Restructuring and other expense for the year ended December 31, consists of the following:
| 2015 |  | 2014 |  | 2013
Facility consolidation costs | $ | 8,016 |  |  | $ | 5,612 |  |  | $ | 6,489 |
Termination of a product offering | — |  |  | — |  |  | $ | 2,137 |
Restructuring costs included in cost of sales | $ | 8,016 |  |  | $ | 5,612 |  |  | $ | 8,626 |
Restructuring costs | $ | 13,655 |  |  | $ | 3,354 |  |  | $ | 8,750 |
Business and asset acquisition costs | 2,543 |  |  | 722 |  |  | — |
Management restructuring costs | — |  |  | 12,546 |  |  | — |
Shareholder activism costs | — |  |  | 3,966 |  |  | — |
Patent dispute and other matters | — |  |  | 3,374 |  |  | 3,206 |
Pension settlement expense | — |  |  | — |  |  | 1,443 |
Restructuring and other expense included in selling and administrative expense | $ | 16,198 |  |  | $ | 23,962 |  |  | $ | 13,399 |
During 2015, we incurred $2.5 million in acquisition related costs associated with the January 4, 2016 acquisition of SurgiQuest, Inc. as further described in Note 15 and other acquisitions during 2015. During 2014, we incurred $0.7 million in costs associated with the EndoDynamix, Inc. acquisition as further described in Note 4. During 2014, we incurred $4.0 million in professional fees related to shareholder activism. During 2014 and 2013, we incurred $3.4 million and $3.2 million, respectively in legal and settlement costs. Legal costs for a patent infringement claim that we settled totaled $1.9 million and $3.2 million in 2014 and 2013, respectively. The 2014 patent infringement claim costs included $0.9 million in settlement costs during the first quarter of 2014. The remaining $1.5 million in 2014 legal costs were associated with a legal matter in which we prevailed at trial and consulting fees. During 2013, we had a higher level of lump sum withdrawals from pension plan participants. This resulted in an acceleration of the recognition of a portion of our projected benefit obligation and we therefore recorded a pension settlement expense of $1.4 million. During 2015, 2014 and 2013, we continued our operational restructuring plan. In 2015, we completed the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. During 2014, we completed the consolidation of our Finland operations into our Largo, Florida and Utica, New York manufacturing facilities and the consolidation of our Westborough, Massachusetts manufacturing operations into our Largo, Florida and Chihuahua, Mexico facilities. We incurred $8.0 million, $5.6 million and $6.5 million in costs associated with the operational restructuring during the years ending December 31, 2015, 2014 and 2013, respectively. These costs were charged to cost of sales and include severance and other charges associated with the consolidation of our Finland, Westborough, Massachusetts and Centennial, Colorado operations. In conjunction with the consolidation of our Centennial, Colorado manufacturing operations, the facility is currently held for sale and classified as a current asset in the Consolidated Balance Sheet. The net book value of this facility at December 31, 2015 was $3.1 million. As part of our ongoing restructuring, the Company discontinued a patient monitoring product offering and incurred $2.1 million in costs which were charged to cost of sales during 2013. During 2015, 2014 and 2013, we restructured certain selling and administrative functions and incurred $13.7 million, $3.4 million and $8.8 million, respectively, in related costs consisting principally of severance charges and, for the 2013 year, also included the write-off of certain patents. During 2014, we incurred $12.5 million in costs associated with restructuring of executive management. These costs include severance payments, accelerated vesting of stock-based compensation awards, accrual of the present value of deferred compensation and other benefits to our then Chief Executive Officer as defined in his termination agreement; accelerated vesting of stock-based compensation awards to certain members of executive management, consulting fees and other benefits earned as further described in our Form 8-K filing on July 23, 2014. We have recorded an accrual in current and other long term liabilities of $7.2 million at December 31, 2015 mainly related to severance costs associated with restructuring. Below is a rollforward of the costs incurred and cash expenditures associated with these activities during 2015, 2014 and 2013:
Balance as of January 1, 2013 |  | $ | 4,123 |  |
Expenses incurred |  | 17,376 |  |
Payments made |  | (18,371 | ) |
Balance as of December 31, 2013 |  | 3,128 |  |
Expenses incurred |  | 21,512 |  |
Payments made |  | (16,386 | ) |
Balance as of December 31, 2014 |  | 8,254 |  |
Expenses incurred |  | 21,671 |  |
Payments made |  | (22,750 | ) |
Balance, December 31, 2015 |  | $ | 7,175 |  |
A significant portion of this accrual will be paid out in 2016.

X
- Definition Restructuring Expense and Other Operating Expense [Text Block] + References No definition available. + Details
Name: | cnmd_RestructuringExpenseandOtherOperatingExpenseTextBlock
Namespace Prefix: | cnmd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Restructuring Expenses and Other Operating Expenses [Abstract] + References No definition available. + Details
Name: | cnmd_RestructuringExpensesandOtherOperatingExpensesAbstract
Namespace Prefix: | cnmd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration